Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study by de Ruijter, Wouter et al.
RESEARCH
UseofFraminghamriskscoreandnewbiomarkerstopredict
cardiovascular mortality in older people: population based
observational cohort study
WouterdeRuijter,generalpractitionerandclinicalresearcher,
1RudiGJWestendorp,professor,
2WillemJJ
Assendelft, professor,
1 Wendy P J den Elzen, clinical researcher,
1 Anton J M de Craen, senior
epidemiologist,
2 Saskia le Cessie, statistician,
3 Jacobijn Gussekloo, professor
1
ABSTRACT
Objectives To investigate the performance of classic risk
factors, and of some new biomarkers, in predicting
cardiovascular mortality in very old people from the
general population with no history of cardiovascular
disease.
Design The Leiden 85-plus Study (1997-2004) is an
observational prospective cohort study with 5 years of
follow-up.
Setting General population of the city of Leiden, the
Netherlands.
Participants Population based sample of participants
aged85years(215womenand87men)withnohistoryof
cardiovascular disease; no other exclusion criteria.
Main measurements Cause specific mortality was
registered during follow-up. All classic risk factors
includedintheFraminghamriskscore(sex,systolicblood
pressure, total and high density lipoprotein cholesterol,
diabetes mellitus, smoking and electrocardiogram based
left ventricular hypertrophy), as well as plasma
concentrationsofthenewbiomarkershomocysteine,folic
acid, C reactive protein, and interleukin 6, were assessed
at baseline.
Results During follow-up, 108 of the 302 participants
died; 32% (35/108) of deaths were from cardiovascular
causes.Classic riskfactors didnot predict cardiovascular
mortality when used in the Framingham risk score (area
under receiver operating characteristic curve 0.53, 95%
confidence interval 0.42 to 0.63) or in a newly calibrated
model (0.53, 0.43 to 0.64). Of the new biomarkers
studied, homocysteine had most predictive power (0.65,
0.55 to 0.75). Entering any additional risk factor or
combination of factors into the homocysteine prediction
model did not increase its discriminative power.
Conclusions In very old people from the general
population with no history of cardiovascular disease,
concentrations of homocysteine alone can accurately
identify those at high risk of cardiovascular mortality,
whereas classic risk factors included in the Framingham
risk score do not. These preliminary findings warrant
validation in a separate cohort.
INTRODUCTION
The prevalence and incidence of cardiovascular
disease increases exponentially with age.
1-3 The abso-
lute numbers of cardiovascular events and deaths that
could theoretically be prevented in older people are
therefore substantial, although reductions in relative
riskmightbesmall(thegeriatricparadox).
4Unsurpris-
ingly, some authors have argued strongly for cardio-
vascular preventive measures in this age group.
5-7
Selectionofolderpeopleforsecondarypreventionis
straightforward, since a history of cardiovascular
disease itself is the strongest predictor of future
cardiovascular morbidity and mortality.
8 In primary
prevention, patients are identified according to the
classicriskfactorsforcardiovasculardisease,including
age,sex,systolicbloodpressure,totalandhighdensity
lipoprotein cholesterol, diabetes mellitus, smoking,
and electrocardiogram based left ventricular
hypertrophy.
9-11 The Framingham risk score, which
includes these classic risk factors, was originally
validated for people aged up to 75 years, but has
nevertheless been much used in older populations, in
theabsenceofanappropriatealternative.
1213However,
the power of classic risk factors to accurately predict
risk of cardiovascular disease seems to diminish with
advancing age.
1114 Observational studies in the oldest
people (≥85 years) have shown that some of these risk
factors become nebulous, or even act in the reverse
direction,atthisage.
15-19Thedebateonthelowefficacy
of primary preventive interventions targeted at classic
riskfactorsinthisagegroupisalsoongoing,fuellingthe
argument that current methods of predicting cardio-
vascular risk in the oldest people might not be
effective.
20-24
Several new biomarkers are effective indicators of
highriskofcardiovasculardisease—namelyCreactive
protein, folic acid, interleukin 6, homocysteine, fibri-
nogen,cystatin C,troponinI,variouslipoproteinsand
apolipoproteins, and natriuretic peptides. Their incre-
mental predictive value beyond that of classic risk
factors, however, is generally small.
25-35 Since the
predictive value of classic risk factors wanes with age,
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effective in older populations, not only when added to
classic risk factors, but also in isolation. The predictive
value of individual new biomarkers in older popula-
tionshasrarelybeenstudied,andfindingsweremostly
inconclusive, except for raised concentrations of
homocysteine and N-terminal pro-brain natriuretic
peptide, which are both associated with an increased
risk of cardiovascular disease in older people.
36-39
Recently, however, a study in a cohort of men aged
71yearsfoundthattheadditionoffournewbiomarkers
to a model with classic risk factors significantly
improved prediction of death from cardiovascular
causes.
40 Data about the performance of combinations
of new biomarkers in isolation from classic risk factors
are still non-existent.
To improve strategies for primary prevention of
cardiovascular disease in the oldest people, we
examined ways to identify those at high risk by
assessing the performance of classic risk factors and
some new biomarkers as predictors of cardiovascular
mortality over five years in people without cardio-
vascular disease at age 85 years.
METHODS
Study design, setting and population
The Leiden 85-plus Study is an observational, pro-
spective, population based cohort study of inhabitants
ofthecityofLeiden,theNetherlands.Itsgeneralaimis
to study determinants of successful ageing in the
general population of the oldest people. Between
September 1997 and September 1999, 705 people in
the 1912-14 birth cohort reached the age of 85 years
and were eligible to participate in the study. No
exclusion criteria were used. Fourteen people died
before enrollment; a total of 599 (87%) people gave
informedconsenttotakepartandwererecruitedtothe
study. All participants were visited at their homes,
where they underwent face to face interviews, blood
sampling, electrocardiography, and functional tests.
For the present study, we excluded all participants
with a history of cardiovascular disease, including
myocardial infarction, stroke, peripheral arterial dis-
ease (intermittent claudication or surgery for non-
cardiac arterial disease), angina pectoris, or heart
failure (n=250 of 599, 42%). To this end, we inter-
viewed participants’ primary care physicians about
these conditions. Since previously unrecognised
(silent) myocardial infarctions are highly prevalent in
old age,
41 we decided to exclude an additional 22
participants because their baseline electrocardiogram
showed evidence of a previous myocardial infarction
(definedasthepresenceofMinnesotacodes1-1or1-2,
excludingcode1-2-8).
4243Finally,25participantswere
excludedbecauseofmissingdataforclassicriskfactors
or new biomarkers, leading to a final sample size of
n=302.
Cardiovascular mortality
Allparticipantswerefollowedupformortalityuntilage
90 years; none was lost to follow-up. Dates of death
wereobtainedfrommunicipalityrecords.Specificdata
on causes of death were obtained from Statistics
Netherlands, where all national death certificates are
coded according to the International Classification of
Diseases and Related Disorders, 10th revision.
44
Causes of death were divided into cardiovascular
causes (codes I00-I99) and non-cardiovascular causes
(all other codes). Assignment of cause of death was
independentoftheriskfactorsthatweredeterminedin
participants at age 85 years.
Classic risk factors in participants at age 85 years
Systolic blood pressure
Blood pressure was measured on two occasions with a
mean interval of two weeks. Systolic blood pressure
was recorded at the onset of Korotkoff phase I. The
mean of the measured systolic values was used for
analyses.
Total and high density lipoprotein cholesterol
Blood samples were obtained for measurement of
serum concentrations of total cholesterol and high
density lipoprotein, which were analysed on fully
automated computerised analysers (Hitachi 747 and
911; Hitachi, Tokyo, Japan).
Smoking
All participants were interviewed about present and
past smoking habits. Current and past smokers of
cigarettes, cigars, and pipes were judged to have a
history of smoking.
Diabetes mellitus
Diabetes mellitus was considered present when the
primary care physician stated so, when non-fasting
glucoseconcentrationsweregreaterthan11.0mmol/l,
orwhen,accordingtopharmacistrecords,aparticipant
was taking diabetes medication.
Electrocardiogram based left ventricular hypertrophy
Electrocardiograms were recorded on a Siemens
Sicard 440 (Erlangen, Germany) and transmitted to
theelectrocardiogramscorelaboratoryintheGlasgow
Royal Infirmary for automated Minnesota coding.
42
All electrocardiograms were reviewed to exclude
coding errors due to technical causes. Left ventricular
hypertrophywasdefinedbyMinnesotacodes310,330,
or 340.
New biomarkers in participants at age 85 years
We selected four of the new biomarkers that had been
measured in the Leiden 85-plus Study: homocysteine
and folic acid from the methionine-homocysteine
pathway, and C reactive protein and interleukin 6 as
markers of inflammation.
Homocysteine
Concentrations of homocysteine were measured in
plasma samples with a fluorescence polarisation
immunoassay after reduction to the free form with an
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cient of variation 2.2-2.5%).
Folic acid
Serum concentrations of folic acid were measured
using the dual count solid phase no boil assay
(Diagnostic Products Corporation, Los Angeles, CA,
USA; coefficient of variation 4.7-7.3%).
C reactive protein
Plasma concentrations of C reactive protein were
measuredusingafullyautomatedHitachi747analyzer
(Hitachi, Tokyo, Japan; detection limit 1 mg/l;
coefficient of variation <5%).
Interleukin 6
Serum concentrations of interleukin 6 were measured
using a standard enzyme linked immunosorbent assay
(Sanquin,Amsterdam,theNetherlands,detectionlimit
4 pg/ml, coefficient of variation 5-10%).
Data analysis
For every participant, we calculated the Framingham
risk score using the modified classic Framingham
equation, with 5 year cardiovascular mortality as the
endpoint(as opposedto 10 yearincidence of coronary
heart disease) and including the weighted risk factors
age,sex,systolicbloodpressure,totalandhighdensity
lipoprotein cholesterol concentrations, smoking, dia-
betes mellitus, and electrocardiogram based left
ventricular hypertrophy.
13 Since all participants were
85 years old, age did not contribute to differences in
absolute risk scores. We assigned participants to high
risk, intermediate risk, and low risk groups based on
tertiles of the calculated Framingham risk scores. We
repeated analyses with different cut-off values for risk
scores (quartiles, deciles).
We constructed seven new prediction models, each
using various combinations of classic risk factors and
newbiomarkers:(1)allclassicriskfactorsinonemodel
(sex, systolic blood pressure, total cholesterol, high
density lipoprotein cholesterol, diabetes mellitus,
present or past smoking, and electrocardiogram
based left ventricular hypertrophy); (2) homocysteine
concentration and sex; (3) folic acidconcentrationand
sex; (4) C reactive protein concentration and sex; (5)
interleukin 6 concentration and sex; (6) homocysteine
concentrationplusallclassicriskfactors;and(7)allfour
new biomarkers and sex. We entered each combina-
tion of risk factors simultaneously in a Cox propor-
tional hazards model, and, for each model, noted for
eachparticipantthelinearpredictorscore(X-β),which
represented their individual predicted risk of cardio-
vascular mortality during the 5 year follow-up period.
Weassignedparticipantstoahigh,intermediate,orlow
risk group on the basis of tertiles of the calculated X-β
values for each model.
We assessed the performance of the different
prediction models with three methods.
45 First, the
tertilesofFraminghamriskscoreswerecomparedwith
the observed 5 year cardiovascular mortality using
Kaplan-Meierplotsandthelogranktest.Hazardratios
with corresponding 95% confidence intervals (3rd
tertile versus 1st tertile as reference) were calculated
using Cox proportional hazard models. Second, using
the continuous risk scores from each model, receiver
operating characteristic curves with corresponding
areas under the curves (neutral value 0.50= risk
prediction by pure chance) and 95% confidence
intervals were constructed, using cardiovascular mor-
tality versus non-cardiovascular mortality or survival
as the outcome. Third, the prediction model based on
homocysteine concentration was compared with the
Framingham risk score by calculating, for each
method, the correctly classified number of partici-
pants—those in the high risk tertile who actually died
from cardiovascular causes during follow-up. Of the
participants who actually died, we calculated the net
percentage of participants who were wrongly assigned
to the intermediate or low risk group by the Framing-
ham risk score, but correctly assigned to the high risk
group by the model based on homocysteine concen-
tration, and we tested this percentage for significance
using McNemar’s test.
46
Sincetheaimofthestudywastoassessthepredictive
performanceoftheriskfactorsandbiomarkers,andnot
to investigate causes of disease, we made no adjust-
ments for potential confounders. To investigate the
validity of the results derived from the prediction
model based on homocysteine, the first two methods
were repeated using cross validated X-β values
obtained by the jackknife method.
47 We analysed
data with SPSS 12.0 for Windows (SPSS, Chicago, IL,
USA). The reporting of this observational study
followed guidelines from the STROBE statement.
48
RESULTS
The table summarises the baseline characteristics and
cardiovascular risk factors of the 302 participants with
nohistoryofcardiovasculardisease.Themajoritywere
women,didnotliveininstitutions,andperformedwell
onthemini-mentalstateexamination.Participants’self
reported quality of life was high. Of the 302 partici-
pants, 108 (36%) died during the 5-year follow-up
period; 35 (32%) of these deaths were caused by
cardiovascular disease.
Figure 1 shows 5-year cardiovascular mortality
depending on risk tertiles based on the Framingham
risk score. We found no differences in cardiovascular
mortalitybetweentheriskcategories(riskratioforhigh
vlowriskcategory1.2,95%confidenceinterval0.51to
2.6). When the Framingham risk factors were entered
as separate variables in a Cox proportional hazard
model to create a prediction model calibrated for very
old people, three new risk categories were obtained,
butthesecategoriesalsodidnotpredicttheobserved5-
yearcardiovascularmortality(fig1;riskratioforhighv
low risk category 1.3, 95% confidence interval 0.57 to
2.7). Accuracy of the model did not improve when the
group was divided at different intervals (risk quartiles,
risk deciles) or after adjustment for use of anti-
hypertensive medication (data not shown).
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predictionmodelsbasedonhomocysteine,folicacid,C
reactive protein, and interleukin 6. Only the model
based on homocysteine resulted in significant differ-
ences between the risk categories (log rank test,
P=0.002); the high risk category had a 3.4-fold (95%
confidence interval 1.4 to 8.1) increased risk of
cardiovascular mortality compared with the low risk
category. This risk did not change after adjustment for
creatinin clearance. The high risk category in the
model based on folic acid had a 2.2-fold (1.0 to 5.0)
increased risk of cardiovascular mortality compared
with the low risk category. The model including both
homocysteineandfolicacid(datanotshowninfigure2)
showednoimprovementofriskpredictionbeyondthe
model with only homocysteine; the high risk category
had a 1.9-fold (1.2 to 2.9) increased risk of cardio-
vascular mortality compared with the low risk cate-
gory.
When the predictive value of the Framingham risk
scoreandtheriskmodelbasedonhomocysteinealone
were compared by receiver operating characteristic
curves (figure 3), the area under the curve for the
Framingham risk score was 0.53 (95% confidence
interval 0.42 to 0.63) and that for the homocysteine-
based model was 0.65 (0.55 to 0.75). For the new
model,usingclassicriskfactorsandcalibratedforvery
old people, the area under the curve was the same as
thatfortheFraminghamriskscoreat0.53(0.43to0.64,
receiver operating characteristic curve not shown).
Combining the Framingham risk score and the model
basedonhomocysteinedidnotincreasediscriminative
power (area under the curve 0.65, 95% confidence
interval0.54to0.75),nordidthepowerincreaseforthe
model based on a combination of all four new
biomarkers(areaunderthecurve0.65,95%confidence
interval 0.55 to 0.75, receiver operating characteristic
curve not shown).
Ofthe35participantswhodiedfromcardiovascular
disease during the 5 year follow-up period, the
Framingham risk score classified 12 participants in
the high risk tertile. According to the model based on
homocysteine, 20 of the 35 participants were classified
in the high risk tertile. Thus, compared with the
Framingham risk score, classification of risk on the
basisofhomocysteineconcentrationsaloneresultedin
a 23% increase in identification of individuals at high
risk (P=0.045).
46
The performance of the model based on homo-
cysteine did not change after cross validation by the
jackknife method using data from the Leiden 85-plus
Study (risk ratio for high v low risk category 3.0, 95%
confidence interval 1.3 to 7.3; data not shown). Cross
validationdidnotmateriallychangethediscriminative
power of the homocysteine based model, as derived
from the receiver operating characteristic curve (area
under the curve 0.62, 95% confidence interval 0.52 to
0.73, receiver operating characteristic curve not
shown).
DISCUSSION
Principal findings
In the cohort of the Leiden 85-plus Study, cardio-
vascular mortality in people at the age of 85 with no
history of cardiovascular disease was not accurately
Baseline characteristics of participants with no history of
cardiovascular disease at age 85 years (n=302)
n (%) or median
(IQR)*
Sociodemographicand functional characteristics
Non-institutional living 255 (84)
Cognitive function (MMSE 0-30) 27 (23-28)
Subjective wellbeing (Cantrils’ ladder 0-10)† 8 (6-9)
Classic risk factors from Framingham risk score
Male gender 87 (29)
Systolic blood pressure (mmHg)‡ 154 (144-167)
Total cholesterol (mmol/L) 5.7 (5.0-6.5)
HDL cholesterol (mmol/L) 1.3 (1.1-1.6)
Diabetes mellitus 43 (14)
Current and/or past smoking 134 (44)
Left ventricular hypertrophy 27 (9)
New biomarkers
Homocysteine (μmol/l) 11.9 (9.7-14.7)
Folic acid (nmol/L) 12.4 (9.6-17.5)
C reactive protein (mg/l) 3 (1-7)
Interleukin 6 (pg/ml) 10 (0-61)
MMSE=mini-mental state examination; HDL=high density lipoprotein.
*Categorical data presented as number (percentage), continuous data as
median (interquartile range).
†n=284, missing data for 18 participants.
‡n=301, missing data for one participant.
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Fig 1 | Cumulative cardiovascular mortality depending on
tertiles of risk obtained from classic risk factors, weighted on
the basis of Framingham risk score, or newly calibrated risk
score from the Leiden 85-plus Study
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in the Framingham risk score. By contrast, a single
measurement of homocysteine accurately identified
those at high risk of cardiovascular mortality. These
resultssuggestthatinthisagegroup,riskidentification
for primary prevention of cardiovascular disease
should be based not on classic risk factors anymore,
but on plasma concentrations of homocysteine.
For decades the Framingham risk score has been
usedtopredictthe10yearriskofdevelopingcoronary
heart disease in people with no history of cardio-
vascular disease.
49 Although it has certainly stood the
test of time for its original purpose, our study confirms
earlierfindingsofafallinthepredictiveabilitiesofthis
risk score in older populations.
1114 Therefore, the
finding of a more accurate measure of cardiovascular
disease risk is very relevant to this population.
The strong association between raised concentra-
tions of homocysteine and cardiovascular morbidity
and mortality has been recognised since 1969,
50 and
has been repeatedly described in various
populations.
29313651-53 We have shown that homocys-
teine, unlike the classic risk factors, remains a potent
predictor of risk in older people. Its predictive power
goes beyond that of classic risk factors, and is equally
robustwithoutclassicriskfactorsbeingincludedinthe
model. These features have rarely been demonstrated
in new biomarkers for cardiovascular disease.
54
By contrast, we were unable to confirm the associa-
tions found in younger age groups between cardio-
vascular disease and concentrations of C reactive
protein, interleukin 6, and folic acid.
26303355 The
weakness of these markers of inflammation, specifi-
callyCreactiveproteinandinterleukin6,inpredicting
cardiovascular mortality in the oldest people is in line
withfindingsofthelargestprospectivestudydedicated
to C reactive protein and cardiovascular disease in
older people to date.
56
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Our study has several strengths. First, the Leiden 85-
plus Study is an observational, prospective study of
oldest people, in which 87% of the general population
participated and follow-up on mortality was complete.
Thesefactorsaddtotheexternalvalidityofourresults.
Indeed, given that this age group is the fastest growing
segment of the general population in industrialised
societies, the findings of the present study might be
particularly important. Furthermore our study partici-
pants generally had good cognitive function, were
mainlynotlivingininstitutions,andweresatisfiedwith
their quality of life.
57 Primary prevention of cardio-
vascular mortality in these very old people may
lengthen independent and contented living, and to
this end effective identification of individuals at high
risk is essential. Another strength of our study is the
consistency of the results across all statistical methods,
includingacrossvalidation,whichsupportsthevalidity
of our findings.
454658
Aweaknessofourstudycouldbethelimitednumber
of new biomarkers that we selected to investigate.
Other biomarkers, as well as new imaging techniques
such as measurement of coronary artery calcium,
59
might have predictive value equal to that of homo-
cysteine in this population. A second limitation of our
study is its relatively small size. Despite a high rate of
events (35/302, 12%), a type 2 error (failure to reject a
nullhypothesisthatisinfactfalse)cannotberuledout.
We thereforerecommendvalidationof ourfindingsin
alargercohort.Anotherpotentialweaknesscouldhave
been differential misclassification in causes of death,
especially in participants with known classic risk
factors.
60 However, such inconsistencies would have
ledtogreaterdifferencesbetweenrisktertilesbasedon
the Framingham risk score. Laboratory results for the
new biomarkers were not reported to clinicians, and
therefore any misclassification was independent of
these test results (non-differential misclassification).
Clinical implications and future research
Westudiedthebestwaytoidentifypatientsathighrisk
(“true prediction”), not the causes that underlie the
observed associations. Hence, although homocysteine
accuratelypredictscardiovascularmortalityinveryold
age,wedonotsuggestthatloweringhomocysteinewill
be beneficial; in fact, so far this approach has been
shown to be ineffective.
61-63 With regard to choosing
effective methods for primary prevention of cardio-
vascular disease, the role of statins needs to be
explored, since their beneficial effect in secondary
prevention in old age is evident.
2164 Since the under-
lyingatheroscleroticprocessisunlikelytochangewith
age, statins could also be effective in primary preven-
tion, if the selection of patients at high risk is accurate.
Conclusions
In this study, a model based on homocysteine
concentration alone was a better predictor of cardio-
vascularmortalityinveryoldpeoplewithnohistoryof
cardiovascular disease than were models based on
classic risk factors. These preliminary findings call for
validationinaseparatecohortand,ifconfirmed,could
eventually lead to a revision of current guidelines and
corresponding indicators of quality of care.
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